Expression, purification, and characterization of human type II arginase

被引:52
作者
Colleluori, DM
Morris, SM
Ash, DE
机构
[1] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA
[2] Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA
关键词
arginase; isozyme; human; mitochondria;
D O I
10.1006/abbi.2001.2324
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human type II arginase, which is extrahepatic and mitochondrial in location, catalyzes the hydrolysis of arginine to form ornithine and urea. While type I arginases function in the net production of urea for excretion of excess nitrogen, type II arginases are believed to function primarily in the net production of ornithine, a precursor of polyamines, glutamate, and proline. Type II arginases may also regulate nitric oxide biosynthesis by modulating arginine availability for nitric oxide synthase, Recombinant human type II arginase was expressed in Escherichia coli and purified to apparent homogeneity. The K-m of arginine for type II arginase is approximately 4.8 mM at physiological pH, Type II arginase exists primarily as a trimer, although higher order oligomers were observed. Borate is a noncompetitive inhibitor of the enzyme, with a K-is of 0.32 mM and a K-ii of 0.3 mM. Ornithine, a product of the reaction catalyzed by arginase and a potent inhibitor of type I arginase, is a poor inhibitor of the type II isozyme. The findings presented here indicate that isozyme-selectivity exists between type I and type II arginases for binding of substrate and products, as well as inhibitors. Therefore, inhibitors with greater isozyme-selectivity for type II arginase may be identified and utilized for the therapeutic treatment of smooth muscle disorders, such as erectile dysfunction. (C) 2001 Academic Press.
引用
收藏
页码:135 / 143
页数:9
相关论文
共 34 条
[1]  
Baggio R, 1999, J PHARMACOL EXP THER, V290, P1409
[2]   Inhibition of Mn-2(2+)-arginase by borate leads to the design of a transition state analogue inhibitor, 2(S)-amino-6-boronohexanoic acid [J].
Baggio, R ;
Elbaum, D ;
Kanyo, ZF ;
Carroll, PJ ;
Cavalli, RC ;
Ash, DE ;
Christianson, DW .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (34) :8107-8108
[3]   Hyperornithinaemia-hyperammonaemia-homocitrullinuria syndrome is caused by mutations in a gene encoding a mitochondrial ornithine transporter [J].
Camacho, JA ;
Obie, C ;
Biery, B ;
Goodman, BK ;
Hu, CA ;
Almashanu, S ;
Steel, G ;
Casey, R ;
Lambert, M ;
Mitchell, GA ;
Valle, D .
NATURE GENETICS, 1999, 22 (02) :151-158
[4]   KINETICS OF INHIBITION OF RAT-LIVER AND KIDNEY ARGINASES BY PROLINE AND BRANCHED-CHAIN AMINO-ACIDS [J].
CARVAJAL, N ;
CEDERBAUM, SD .
BIOCHIMICA ET BIOPHYSICA ACTA, 1986, 870 (02) :181-184
[5]   MUTAGENESIS OF RAT-LIVER ARGINASE EXPRESSED IN ESCHERICHIA-COLI - ROLE OF CONSERVED HISTIDINES [J].
CAVALLI, RC ;
BURKE, CJ ;
KAWAMOTO, S ;
SOPRANO, DR ;
ASH, DE .
BIOCHEMISTRY, 1994, 33 (35) :10652-10657
[6]   STABILITY OF METAL CHELATES .2. BETA-HYDROXYETHYLIMINODIACETIC ACID [J].
CHABEREK, S ;
COURTNEY, RC ;
MARTELL, AE .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1952, 74 (20) :5057-5060
[7]  
CHEUNG CW, 1989, J BIOL CHEM, V264, P4038
[8]  
Cleland W W, 1979, Methods Enzymol, V63, P103
[9]  
Cox JD, 1999, NAT STRUCT BIOL, V6, P1043
[10]  
GLICK B, 1991, ANNU REV GENET, V25, P21